{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "wsmg:health-sciences/medicine/nephrology/neph-019",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:53:50.000Z",
    "modified": "2026-01-13T13:24:00.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "quality-agent"
    ],
    "confidence": 0.96,
    "status": "validated",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/nephrology",
    "subdomain": "glomerular-diseases",
    "type": "definition",
    "difficulty": "advanced",
    "importance": "high",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "ANCA-Associated Vasculitis - Renal Manifestations",
    "summary": "ANCA-associated vasculitis (AAV) represents a group of small-vessel vasculitides (GPA, MPA, EGPA) that commonly cause pauci-immune crescentic glomerulonephritis. Renal involvement is characterized by rapidly progressive glomerulonephritis (RPGN), requiring urgent diagnosis and immunosuppressive therapy to preserve kidney function.",
    "key_points": [
      "Three AAV types: GPA (c-ANCA/PR3), MPA (p-ANCA/MPO), EGPA (p-ANCA with eosinophilia)",
      "Pauci-immune GN: Crescentic GN with absent/minimal immune deposits on IF",
      "RPGN presentation: AKI, hematuria, proteinuria, RBC casts over days to weeks",
      "Pulmonary-renal syndrome: Concurrent diffuse alveolar hemorrhage (DAH) is emergency",
      "Treatment: Rituximab or cyclophosphamide + glucocorticoids for induction",
      "Plasmapheresis for severe renal disease (creatinine >5.7) or DAH"
    ],
    "statement": "ANCA-associated vasculitis causes pauci-immune crescentic glomerulonephritis manifesting as rapidly progressive renal failure, requiring prompt recognition and aggressive immunosuppression to prevent irreversible kidney damage.",
    "explanation": {
      "intuition": "Think of ANCA as 'friendly fire' - antibodies that mistakenly target neutrophils, causing them to attack small blood vessels including glomerular capillaries. The resulting inflammation destroys the glomerulus rapidly, forming crescents (like the moon shape) of proliferating cells that obliterate the filtering space.",
      "key_insight": "The 'pauci-immune' nature is key: unlike other glomerulonephritides with prominent immune deposits, AAV shows minimal deposits because the damage is from activated neutrophils rather than immune complex deposition. ANCA testing plus biopsy showing crescentic GN with absent IF staining clinches the diagnosis.",
      "technical_details": "PR3-ANCA (c-ANCA pattern) is associated with GPA; MPO-ANCA (p-ANCA pattern) with MPA and EGPA. ANCA activate primed neutrophils to release toxic contents and adhere to endothelium. Biopsy shows segmental fibrinoid necrosis, cellular/fibrocellular crescents, and negative or 'pauci' (<2+) immunofluorescence."
    },
    "definitions_glossary": {
      "ANCA": "Anti-neutrophil cytoplasmic antibodies targeting neutrophil granule proteins",
      "GPA": "Granulomatosis with polyangiitis (formerly Wegener's); upper/lower respiratory + renal",
      "MPA": "Microscopic polyangiitis; renal-dominant or pulmonary-renal without granulomas",
      "EGPA": "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss); asthma + eosinophilia",
      "pauci_immune": "Absence or paucity of immunoglobulin/complement on immunofluorescence",
      "crescentic_GN": "Glomerulonephritis with crescent formation in >50% of glomeruli on biopsy",
      "RPGN": "Rapidly progressive glomerulonephritis; renal failure over days to weeks",
      "PR3_ANCA": "Proteinase 3 antibodies; cytoplasmic (c-ANCA) pattern; associated with GPA",
      "MPO_ANCA": "Myeloperoxidase antibodies; perinuclear (p-ANCA) pattern; MPA/EGPA",
      "DAH": "Diffuse alveolar hemorrhage; life-threatening pulmonary complication",
      "pulmonary_renal_syndrome": "Concurrent pulmonary hemorrhage and glomerulonephritis",
      "BVAS": "Birmingham Vasculitis Activity Score; standardized disease activity measure"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "mechanism": "ANCA bind to surface-expressed PR3 or MPO on primed neutrophils, causing activation, endothelial adhesion, and release of toxic granule contents leading to small vessel necrosis",
      "disease_subtypes": {
        "GPA": {
          "ANCA_type": "PR3-ANCA (c-ANCA) in 80-90%",
          "classic_features": ["Upper respiratory (sinusitis, saddle nose)", "Lower respiratory (nodules, cavities)", "Renal (crescentic GN)"],
          "renal_involvement": "80% develop renal disease"
        },
        "MPA": {
          "ANCA_type": "MPO-ANCA (p-ANCA) in 60-80%",
          "classic_features": ["Renal-dominant disease", "Pulmonary capillaritis", "No granulomas"],
          "renal_involvement": ">90% have renal involvement"
        },
        "EGPA": {
          "ANCA_type": "MPO-ANCA in 40%; ANCA-negative in 60%",
          "classic_features": ["Asthma", "Eosinophilia", "Neuropathy", "Cardiac involvement"],
          "renal_involvement": "25% have renal disease (usually less severe)"
        }
      },
      "renal_pathology": {
        "light_microscopy": ["Segmental fibrinoid necrosis", "Cellular crescents", "Focal/diffuse pattern"],
        "immunofluorescence": "Negative or pauci-immune (<2+ staining)",
        "electron_microscopy": "No electron-dense deposits"
      }
    },
    "diagnostic_criteria": {
      "clinical_presentation": [
        "Rapidly progressive AKI (creatinine doubling over weeks)",
        "Active urine sediment: dysmorphic RBCs, RBC casts",
        "Proteinuria (usually subnephrotic)",
        "Constitutional symptoms: fever, weight loss, fatigue",
        "Multisystem involvement (pulmonary, ENT, skin, nerves)"
      ],
      "laboratory_findings": [
        "Positive ANCA (PR3 or MPO) by ELISA",
        "Elevated creatinine with active sediment",
        "Elevated CRP/ESR",
        "Anemia of chronic disease"
      ],
      "renal_biopsy_findings": [
        "Crescentic GN (>50% crescents = severe)",
        "Fibrinoid necrosis",
        "Pauci-immune IF pattern",
        "Classification: focal, crescentic, mixed, sclerotic"
      ]
    },
    "differential_diagnosis": [
      "Anti-GBM disease (linear IgG on IF)",
      "Immune complex GN (lupus nephritis, IgA)",
      "Infection-related GN",
      "Drug-induced ANCA (hydralazine, propylthiouracil)"
    ],
    "treatment_options": {
      "induction_therapy": {
        "mild_moderate": "Rituximab 375mg/mÂ² weekly x 4 OR cyclophosphamide + high-dose glucocorticoids",
        "severe": "Rituximab or cyclophosphamide + plasmapheresis if creatinine >5.7 mg/dL or DAH",
        "glucocorticoids": "Pulse methylprednisolone 500-1000mg x 3 days, then oral prednisone taper"
      },
      "maintenance_therapy": {
        "rituximab": "500mg every 6 months for 2+ years (preferred)",
        "azathioprine": "2 mg/kg/day alternative",
        "duration": "Minimum 2 years after remission"
      },
      "supportive_care": [
        "RRT if needed (recovery possible)",
        "PJP prophylaxis (TMP-SMX)",
        "Bone protection with glucocorticoid use"
      ]
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "ANCA-Associated Vasculitis Renal Disease"
    },
    "altLabel": [
      {"@language": "en", "@value": "AAV nephritis"},
      {"@language": "en", "@value": "Pauci-immune crescentic glomerulonephritis"},
      {"@language": "en", "@value": "ANCA vasculitis kidney involvement"}
    ],
    "definition": {
      "@language": "en",
      "@value": "Renal manifestation of ANCA-associated small vessel vasculitis, characterized by pauci-immune crescentic glomerulonephritis and rapidly progressive renal failure"
    },
    "notation": "neph-019",
    "scopeNote": {
      "@language": "en",
      "@value": "Focuses on renal involvement in GPA, MPA, and EGPA with diagnosis and treatment"
    }
  },
  "relationships": {
    "skos:broader": [
      {
        "@id": "wsmg:health-sciences/medicine/nephrology/glomerulonephritis",
        "skos:prefLabel": "Glomerulonephritis"
      }
    ],
    "skos:narrower": [],
    "skos:related": [
      {
        "@id": "wsmg:health-sciences/medicine/nephrology/neph-018",
        "skos:prefLabel": "Anti-GBM Disease"
      },
      {
        "@id": "wsmg:health-sciences/medicine/nephrology/neph-011",
        "skos:prefLabel": "Glomerulonephritis Overview"
      },
      {
        "@id": "wsmg:health-sciences/medicine/rheumatology/vasculitis",
        "skos:prefLabel": "Systemic Vasculitis"
      }
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/ANCA-associated_vasculitis"
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "239934006",
      "uri": "http://snomed.info/id/239934006",
      "description": "Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "M31.7",
      "uri": "http://hl7.org/fhir/sid/icd-10-cm/M31.7",
      "description": "Microscopic polyangiitis"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D055953",
      "uri": "http://id.nlm.nih.gov/mesh/D055953",
      "description": "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Differentiate GPA, MPA, and EGPA by clinical and serologic features",
      "Recognize RPGN presentation requiring urgent biopsy",
      "Interpret pauci-immune pattern on immunofluorescence",
      "Select appropriate induction and maintenance therapy",
      "Identify indications for plasmapheresis in AAV"
    ],
    "clinical_pearls": [
      "ANCA-negative AAV exists (~10%) - biopsy is still diagnostic",
      "Drug-induced ANCA (PTU, hydralazine) is usually MPO-ANCA positive",
      "Rituximab non-inferior to cyclophosphamide for induction (RAVE trial)",
      "Pulmonary-renal syndrome = emergency; start treatment before biopsy",
      "Recovery from dialysis-dependence possible with aggressive treatment"
    ],
    "board_yield": "HIGH",
    "estimated_time": "25min",
    "target_audience": [
      "nephrology_fellows",
      "rheumatology_fellows",
      "internal_medicine_residents"
    ],
    "common_misconceptions": [
      "All AAV is ANCA-positive - 10% are ANCA-negative",
      "Dialysis-dependent = irreversible - recovery possible with treatment",
      "PR3 always means GPA - MPO can occur in GPA too"
    ]
  },
  "prerequisites": [
    {
      "@id": "wsmg:health-sciences/medicine/nephrology/neph-011",
      "skos:prefLabel": "Glomerulonephritis Overview"
    }
  ],
  "related_concepts": [
    "ANCA testing",
    "crescentic GN",
    "rituximab",
    "cyclophosphamide",
    "renal biopsy"
  ],
  "evidence": {
    "citations": [
      {
        "authors": "Stone JH, Merkel PA, Spiera R, et al.",
        "title": "Rituximab versus cyclophosphamide for ANCA-associated vasculitis",
        "journal": "N Engl J Med",
        "year": 2010,
        "volume": "363",
        "pages": "221-232",
        "doi": "10.1056/NEJMoa0909905"
      }
    ],
    "confidence_rationale": "Based on RAVE trial and KDIGO guidelines"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-13T13:24:00.000Z",
    "sources": [
      {
        "source": "KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases",
        "type": "guideline",
        "year": 2021,
        "relevance": "Evidence-based management of AAV"
      },
      {
        "source": "Brenner and Rector's The Kidney, 11th ed. Elsevier, 2020.",
        "type": "textbook",
        "year": 2020,
        "isbn": "978-0323532655",
        "relevance": "Comprehensive nephrology reference"
      }
    ]
  },
  "quality_assessment": {
    "content_quality_score": 0.94,
    "completeness": 0.95,
    "accuracy": 0.96,
    "clarity": 0.93,
    "clinical_relevance": 0.97,
    "last_assessed": "2026-01-13T13:24:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/ANCA-associated_vasculitis",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q4651648"
}